Can This Forgotten Coronavirus Stock Make You Rich?

Last year, biotech company Gilead Sciences (NASDAQ: GILD) rose in prominence thanks to antiviral medicine Veklury, which was sometimes touted as the most promising potential treatment for COVID-19. But a lot has happened since then for the drugmaker, and in the past 12 months, Gilead Sciences' stock has underperformed the broader market, as the following graph illustrates.

This poor showing does have one silver lining, though. Shares of Gilead Sciences are reasonably valued at 9.7 times forward earnings, compared with an estimated forward price-to-earnings ratio of 21 for the S&P 500. If there is a rebound in the cards for the biotech -- and if it can soundly beat the market from here on out -- initiating a position in Gilead Sciences at current prices will pay rich dividends down the road. 

Continue reading

Source Fool.com